FeesSafety
Pluang+

Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027

Market News
19 Aug 2026, 18:44 WIB
Seeking Alpha
View Source
Bullish
Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027

Jade Biosciences is developing JADE101, a selective APRIL inhibitor for IgA nephropathy (IgAN), aiming for quarterly dosing to improve patient adherence compared to competitors. Phase 1 data show JADE101 reduces IgA levels by about 70% with a good safety profile. The upcoming Phase 2 JUNIPER trial interim results, expected in 2027, will be critical for the drug's future. The company also has other candidates designed for extended dosing intervals, supported by $461 million in cash to fund development through 2028, though risks remain from clinical translation and competition.

More News

LEPAS launches premium electric vehicles in the Middle East, starting with the L8 PHEV in Dubai.

LEPAS launches premium electric vehicles in the Middle East, starting with the L8 PHEV in Dubai.

LEPAS, Chery Auto's premium new energy vehicle brand, officially entered the Middle East market with a launch event in Dubai showcasing its L8, L6, and L4 models. The L8 PHEV, which has been tested across Gulf countries, will lead the rollout, offeri...

Market News
Bullish
1 hour ago
Nvidia's memory supply commitments soar to $390B, boosting Micron's growth outlook.

Nvidia's memory supply commitments soar to $390B, boosting Micron's growth outlook.

Nvidia's fiscal third-quarter report revealed a jump in supply commitments from $279 billion to $390 billion, mainly for memory chips. This surge signals strong demand for memory suppliers like Micron Technology, which is working with Nvidia on a cus...

Market News
Bullish
2 hours ago
Pixalate launches OpenEPG DB™ on AWS RTB Fabric for detailed CTV ad targeting by show and genre.

Pixalate launches OpenEPG DB™ on AWS RTB Fabric for detailed CTV ad targeting by show and genre.

Pixalate introduced OpenEPG DB™ 1.0 on Amazon Web Services RTB Fabric, enabling programmatic connected TV (CTV) ad bids to include detailed show, channel, genre, and content rating information. Covering over 770,000 U.S. streaming shows and 17,900 ch...

Others
Bullish
2 hours ago
Pixalate launches 4D invalid traffic blocking on AWS RTB Fabric for programmatic CTV and mobile apps.

Pixalate launches 4D invalid traffic blocking on AWS RTB Fabric for programmatic CTV and mobile apps.

Pixalate has introduced its 4D Invalid Traffic (IVT) Blocking modules on Amazon Web Services (AWS) RTB Fabric, targeting programmatic Connected TV (CTV) and mobile app advertising. These modules filter out invalid traffic at multiple levels— infrastr...

Others
Bullish
3 hours ago
IBM's software revenue grows 9% in Q3, boosting profit and supporting a $300 stock price forecast by 2030.

IBM's software revenue grows 9% in Q3, boosting profit and supporting a $300 stock price forecast by 2030.

IBM's software revenue rose 9% year-over-year in Q3 2026, accelerating from 5% in Q2 and improving profit margins to 35%. This growth drives much of IBM's profits, with software accounting for 65% of segment profit despite being 46% of revenue. Adjus...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App